清热燥湿凉血方协同过表达miR-200b的BMSCs对UC相关性癌变上皮-间质转分化的影响

It has been recognized that the risk of developing colorectal cancer (CRC) is increased in patients with longstanding inflammatory bowel disease (IBD). Epithelial-mesenchymal transition (EMT) may promote CRC progression and metastasis and miR-200 family is considered to be an important molecular regulation of EMT. EMT and the invasion of colorectal cancer caused by the reduced expression of miR -200, which through EMT and mesenchymal to epithelial transition (MET) to participate in the process of primary tumor cell metastasis. Therefore , miR - 200b may regulate EMT as a breakthrough point, thereby inhibiting tumor progression and metastasis.The project intends to treat CRC through gene-modified bone marrow mesenchymal stem cells, while heat and dampness therapy due to has a synergistic effect. In our studies, we will carry miR - 200b gene by a lentivirus, meanwhile, the impact and mechanism of BMSCs with overexpression of miR-200b on epithelial-mesenchymal transition in Ulcerative Colitis Related Colorectal Cancer will be researched. We hope that all our efforts will help lay a sound foundation on finding the potential targets to Ulcerative Colitis Related Colorectal Cancer therapy.

长期处于溃疡性结肠炎（UC）的患者罹患结直肠癌(CRC）的风险较高，上皮-间质转分化（EMT）促进CRC的进展和转移，miR-200家族被认为是调控 EMT的重要分子，与肿瘤的关系备受关注。miR -200的表达减少引起的EMT和基底膜的降解与大肠癌的浸润相关。miR- 200通过EMT和间充质-上皮转化（MET）参与到原发肿瘤细胞转移的过程。所以，miR - 200b可能作为调控EMT的突破点，从而抑制肿瘤的进展及转移。本项目拟通过慢病毒携带miR - 200b基因，得到过表达miR - 200b的骨髓间充质干细胞，控制EMT以缓解和治疗CRC，同时清热燥湿凉血方对基因修饰的骨髓间充质干细胞治疗起到协同作用。本课题通过免疫组化、分子生物学等方法，研究清热燥湿凉血方协同BMSCs抑制EMT从而缓解UCRCC的进展和转移，为开拓该病的临床治疗手段提供新的理论依据和研究方法。

长期处于溃疡性结肠炎（UC）的患者罹患结直肠癌(CRC）的风险较高，上皮-间质转分化（EMT）促进CRC的进展和转移，miR-200家族被认为是调控 EMT的重要分子，与肿瘤的关系备受关注。miR -200的表达减少引起的EMT和基底膜的降解与大肠癌的浸润相关。miR- 200通过EMT和间充质-上皮转化（MET）参与到原发肿瘤细胞转移的过程。所以，miR - 200b可能作为调控EMT的突破点，从而抑制肿瘤的进展及转移。本项目拟通过慢病毒携带miR - 200b基因，得到过表达miR - 200b的骨髓间充质干细胞，控制EMT以缓解和治疗CRC，同时清热燥湿凉血方对基因修饰的骨髓间充质干细胞治疗起到协同作用。本课题通过免疫组化、分子生物学等方法，研究清热燥湿凉血方协同BMSCs抑制EMT从而缓解UCRCC的进展和转移，为开拓该病的临床治疗手段提供新的理论依据和研究方法。